Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Economic Burden of Auto- and Allo-HCT Evaluated

J Med Econ; ePub 2017 Aug 24; Bonafede, et al

Using hematopoietic cell transplantation (HCT) in patients with hematologic malignancies results in considerable direct healthcare costs, according to a study involving >10,500 individuals. Participants included those with hematologic malignancies who received autologous or allogenic HCT between 2011 and 2014 (n=2,672) and matched controls who did not receive HTC (n=7,855). Investigators looked at healthcare resource use in each group. Among the results:

  • Nearly two-thirds of transplant recipients received auto-HCT.
  • Over a 1.5-year observation period, auto-HCT recipients had nearly $314,000 higher all-cause costs than controls.
  • More than half of the cost was related to inpatient admission; one-third to outpatient services, and 13% to prescriptions.
  • All-cause costs for allo-HCT recipients were nearly $622,000 higher vs controls.
  • Three-fourths of the cost was related to inpatient admission; 22% to outpatient services; and 2% to prescriptions.

Citation:

Bonafede M, Richhariya A, Cai Q, et al. Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies. [Published online ahead of print August 24, 2017]. J Med Econ. doi:10.1080/13696998.2017.1364648.